BackTable / Urology / Podcast / Episode #239

Insights on Management of Upper Tract Urothelial Cancer

with Dr. Jeannie Hoffman-Censits and Dr. Bogdana Schmidt

With so many treatment modalities for upper tract urothelial carcinoma, how does new evidence inform optimal care? In this episode of BackTable Tumor Board, urologic oncologist Dr. Nirmish Singla (Johns Hopkins), medical oncologist Dr. Jeannie Hoffman-Censits (Johns Hopkins), and urologic oncologist Dr. Bogdana Schmidt discuss treatment and diagnosis of upper tract urothelial carcinoma (UTUC).

This podcast is supported by:

Ferring Pharmaceuticals

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Insights on Management of Upper Tract Urothelial Cancer with Dr. Jeannie Hoffman-Censits and Dr. Bogdana Schmidt on the BackTable Urology Podcast

Ep 239 Insights on Management of Upper Tract Urothelial Cancer with Dr. Jeannie Hoffman-Censits and Dr. Bogdana Schmidt

00:00 / 01:04

BackTable, LLC (Producer). (2025, June 10). Ep. 239 – Insights on Management of Upper Tract Urothelial Cancer [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Jeannie Hoffman-Censits

Dr. Jeannie Hoffman-Censits is a medical oncologist at Johns Hopkins in Baltimore, Maryland.

Dr. Bogdana Schmidt

Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.

Dr. Nirmish Singla

Dr. Nirmish Singla is the director of translational research in genitourinary oncology at Johns Hopkins University in Baltimore, Maryland.

Synopsis

The discussion covers real-world UTUC cases, highlighting diagnostic challenges, treatment options, and evidence-based management strategies. They address scenarios ranging from localized to advanced UTUC, the role of systemic therapies, perioperative treatments, and the potential for novel approaches with immune checkpoint inhibitors. The episode underscores the evolving landscape of UTUC treatment and the importance of clinical trials and emerging biomarkers in improving patient outcomes.

Timestamps

00:00 - Introduction
02:49 - Case Study 1: 66-Year-Old Male with UTUC
11:19 - Case Study 2: 73-Year-Old Male with High-Grade Urothelial Carcinoma
28:11 - Intravesical Chemotherapy Protocols
30:44 - Case Study 3: 57-Year-Old Male with Recurrent Urothelial Cancer
41:25 Clinical Trials and Emerging Treatments
45:40 Case Study: 55-Year-Old Female with Bulky Lymphadenopathy
56:45 Concluding Remarks and Future Directions

Resources

Society of Urologic Oncology
https://suonet.org/home.aspx

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart on the BackTable Urology Podcast

Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill on the BackTable Urology Podcast

Guide to Patient-Centered Counseling in NMIBC Care with Dr. Sima Porten and Dr. Patrick Hensley on the BackTable Urology Podcast

Contemporary Diagnostics in NMIBC: Clinical Insights with Dr. Anne Schuckman and Dr. Piyush Agarwal on the BackTable Urology Podcast

Renal Cancer Management: Tumor Board Discussion & Treatments with Dr. Raquib Hannan, Dr. Brandon Manley and Dr. Rana McKay on the BackTable Urology Podcast

Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast

Articles

Topics

Upper Tract Urothelial Carcinoma (UTUC) Condition Overview

Learn about Urologic Oncology on BackTable Urology

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.